BMO Capital Markets Raises Celgene Corporation (CELG) Price Target to $155.00

Celgene Corporation (NASDAQ:CELG) had its price target raised by research analysts at BMO Capital Markets from $148.00 to $155.00 in a research note issued on Friday. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ target price would suggest a potential upside of 48.90% from the stock’s current price.

CELG has been the topic of a number of other reports. Vetr lowered Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $146.88 price objective on the stock. in a research report on Tuesday, August 29th. Royal Bank Of Canada decreased their price objective on Celgene Corporation from $166.00 to $148.00 and set a “top pick” rating on the stock in a research report on Friday, October 27th. Leerink Swann reiterated a “buy” rating and issued a $156.00 price objective on shares of Celgene Corporation in a research report on Friday, October 20th. Morgan Stanley decreased their price objective on Celgene Corporation from $120.00 to $115.00 and set an “underweight” rating on the stock in a research report on Monday, October 23rd. Finally, Cantor Fitzgerald reiterated a “buy” rating on shares of Celgene Corporation in a research report on Monday, August 28th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have issued a buy rating and two have issued a strong buy rating to the company. Celgene Corporation currently has a consensus rating of “Buy” and an average target price of $139.87.



Celgene Corporation (NASDAQ CELG) traded up $0.75 during mid-day trading on Friday, reaching $104.10. The company had a trading volume of 5,840,264 shares, compared to its average volume of 4,716,514. Celgene Corporation has a 12-month low of $94.55 and a 12-month high of $147.17. The firm has a market cap of $81,960.00, a PE ratio of 15.68, a price-to-earnings-growth ratio of 0.77 and a beta of 1.79. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The firm had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same period last year, the firm posted $1.58 EPS. The business’s revenue was up 10.2% on a year-over-year basis. equities research analysts forecast that Celgene Corporation will post 6.67 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://ledgergazette.com/2017/11/17/bmo-capital-markets-raises-celgene-corporation-celg-price-target-to-155-00.html.

In related news, insider Terrie Curran sold 1,727 shares of Celgene Corporation stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the transaction, the insider now owns 3,925 shares in the company, valued at $564,768.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael D. Casey sold 9,250 shares of Celgene Corporation stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $139.03, for a total value of $1,286,027.50. Following the transaction, the director now owns 9,250 shares of the company’s stock, valued at approximately $1,286,027.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 20,227 shares of company stock worth $2,843,956. 0.95% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of CELG. Thompson Davis & CO. Inc. boosted its holdings in shares of Celgene Corporation by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 43 shares during the period. Arcadia Investment Management Corp MI boosted its holdings in shares of Celgene Corporation by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 400 shares during the period. Robecosam AG bought a new stake in shares of Celgene Corporation during the third quarter worth approximately $114,000. Harel Insurance Investments & Financial Services Ltd. bought a new stake in shares of Celgene Corporation during the first quarter worth approximately $118,000. Finally, Guidant Wealth Advisors bought a new stake in shares of Celgene Corporation during the third quarter worth approximately $119,000. Institutional investors and hedge funds own 79.16% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply